133 related articles for article (PubMed ID: 10907956)
1. Cost-analysis of high-dose chemotherapy and peripheral blood stem-cell support in patients with solid tumors.
Astier MP; Mayordomo JI; Abad JM; Gómez LI; Tres A
Ann Oncol; 2000 May; 11(5):603-6. PubMed ID: 10907956
[TBL] [Abstract][Full Text] [Related]
2. Modelling cost-effectiveness of high-dose chemotherapy as treatment for relapsed aggressive non-Hodgkin lymphoma in an Australian setting.
Prajogo J; Neil A; Duke J; Zhang H; Stokes B; Rowlings P
Intern Med J; 2009 Aug; 39(8):519-26. PubMed ID: 19732200
[TBL] [Abstract][Full Text] [Related]
3. Costs of high-dose chemotherapy and peripheral blood progenitor cell autograft for breast cancer.
De Rosa L; Lalle M; Pandolfi A; Pescador L
Bone Marrow Transplant; 2001 May; 27(10):1031-5. PubMed ID: 11438817
[TBL] [Abstract][Full Text] [Related]
4. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.
Lee SM; Radford JA; Dobson L; Huq T; Ryder WD; Pettengell R; Morgenstern GR; Scarffe JH; Crowther D
Br J Cancer; 1998 Apr; 77(8):1294-9. PubMed ID: 9579836
[TBL] [Abstract][Full Text] [Related]
6. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
7. Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma.
Mishra V; Vaaler S; Brinch L
Clin Lab Haematol; 2003 Jun; 25(3):179-84. PubMed ID: 12755795
[TBL] [Abstract][Full Text] [Related]
8. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991.
Bennett CL; Armitage JL; Armitage GO; Vose JM; Bierman PJ; Armitage JO; Anderson JR
J Clin Oncol; 1995 Apr; 13(4):969-73. PubMed ID: 7707125
[TBL] [Abstract][Full Text] [Related]
9. Pharmaco-economic study of intensive chemotherapy with peripheral blood progenitor cell support for advanced breast cancer.
Pinguet F; Savelli K; Petit I; Gerbi-Benmansour Y; Fabbro M
Oncol Rep; 2001; 8(5):1013-7. PubMed ID: 11496307
[TBL] [Abstract][Full Text] [Related]
10. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial.
Hartmann O; Le Corroller AG; Blaise D; Michon J; Philip I; Norol F; Janvier M; Pico JL; Baranzelli MC; Rubie H; Coze C; Pinna A; Méresse V; Benhamou E
Ann Intern Med; 1997 Apr; 126(8):600-7. PubMed ID: 9103126
[TBL] [Abstract][Full Text] [Related]
12. Use of high-dose chemotherapy plus granulocyte colony-stimulating factor for the salvage of refractory or resistant-relapse lymphoma patients without stem cell support.
Koç H; Arslan O; Gürman G; Akan H; Ozcan M; Ilhan O; Aydoğdu I; Arat M; Beksaç M; Konuk N; Uysal A
Acta Haematol; 1997; 98(3):136-9. PubMed ID: 9352743
[TBL] [Abstract][Full Text] [Related]
13. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.
Vellenga E; van Agthoven M; Croockewit AJ; Verdonck LF; Wijermans PJ; van Oers MH; Volkers CP; van Imhoff GW; Kingma T; Uyl-de Groot CA; Fibbe WE
Br J Haematol; 2001 Aug; 114(2):319-26. PubMed ID: 11529850
[TBL] [Abstract][Full Text] [Related]
14. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
Fontelonga A; Kelly AJ; MacKintosh FR; Hall S; Monroe P; Wilson GS; Shaft D; Ruthven A; Ascensao JL
Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642
[TBL] [Abstract][Full Text] [Related]
15. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients.
Woronoff-Lemsi MC; Arveux P; Limat S; Deconinck E; Morel P; Cahn JY
Bone Marrow Transplant; 1997 Dec; 20(11):975-82. PubMed ID: 9422478
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma: results of outpatient treatment in community cancer centers.
Weaver CH; Schwartzberg L; Zhen B; Mangum M; Leff R; Tauer K; Rosenberg A; Pendergrass K; Kaywin P; Hainsworth J; Greco FA; West WH; Buckner CD
Bone Marrow Transplant; 1997 Nov; 20(9):753-60. PubMed ID: 9384477
[TBL] [Abstract][Full Text] [Related]
19. Cost determinants in aggressive non-Hodgkin's lymphoma.
van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
[TBL] [Abstract][Full Text] [Related]
20. Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy.
Limat S; Woronoff-Lemsi MC; Milpied N; Chartrin I; Ifrah N; Deconinck E; Gressin R; Colombat P; Cahn JY; Arveux P;
Eur J Cancer; 2000 Dec; 36(18):2360-7. PubMed ID: 11094310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
